骨髓间充质干细胞治疗肺动脉高压的研究进展

Progression of the pulmonary artery hypertension treatment with bone marrow mesenchymal stem cells

肺动脉高压是一组以肺血管阻力持续增加为主要特征的临床综合征，其病因和发病机制未明，临床治疗困难，预后较差。干细胞是一类具有多向分化潜能的祖细胞，能够修复受损的内皮细胞、调节血管舒缩物质的比例，纠正钾通道异常，抑制炎症反应，补充内皮源性祖细胞等，给肺动脉高压的治疗带来了新的曙光。

Pulmonary artery hypertension is a sustained increase in pulmonary vascular resistance as the main feature of the clinical syndrome, its etiology and pathogenesis is unknown, the difficulties of clinical treatment, the prognosis is poor. Stem cells are progenitor cells with multilineage differentiation potential, and able to repair damaged endothelial cells, regulating the proportion of vasomotor substances, to correct the abnormalities of potassium channels, inhibition of the inflammatory response, complement of endothelium-derived progenitor ceils, etc,to pulmonary artery hypertension the treatment has brought a new dawn. Bone marrow mesenchymal stem cells to treat pulmonary artery hypertension progress are reviewed.